RBC Capital May Have Just Lost Faith in Epizyme (NASDAQ:EPZM)

November 14, 2017 - By Dolores Ford

 RBC Capital May Have Just Lost Faith in Epizyme (NASDAQ:EPZM)

Investors sentiment increased to 1.93 in Q2 2017. Its up 0.87, from 1.06 in 2017Q1. It is positive, as 13 investors sold Epizyme Inc shares while 17 reduced holdings. 25 funds opened positions while 33 raised stakes. 47.46 million shares or 3.38% more from 45.91 million shares in 2017Q1 were reported.

The Illinois-based Gp One Trading Lp has invested 0% in Epizyme Inc (NASDAQ:EPZM). Woodstock Corp invested 0.11% in Epizyme Inc (NASDAQ:EPZM). Bb&T Limited Liability Co holds 0% or 12,000 shares. California-based First Republic Invest Mngmt has invested 0% in Epizyme Inc (NASDAQ:EPZM). Millennium Mgmt Limited Liability Company stated it has 0.01% of its portfolio in Epizyme Inc (NASDAQ:EPZM). Fmr Limited Co has 0.01% invested in Epizyme Inc (NASDAQ:EPZM). Financial Architects has invested 0.01% in Epizyme Inc (NASDAQ:EPZM). Deerfield Mngmt invested 0.53% of its portfolio in Epizyme Inc (NASDAQ:EPZM). Capital Fund Management holds 22,900 shares. Ny State Common Retirement Fund holds 41,400 shares or 0% of its portfolio. Renaissance Techs Limited Liability Co reported 200,788 shares stake. 1,955 were accumulated by Royal Financial Bank Of Canada. Baker Bros Advsr Lp stated it has 232,481 shares. Rock Springs Mgmt Lp holds 0.9% of its portfolio in Epizyme Inc (NASDAQ:EPZM) for 1.18M shares. Price T Rowe Assoc Inc Md accumulated 14,712 shares.

Since May 25, 2017, it had 0 insider purchases, and 2 sales for $275,289 activity. Ho Peter Tai-Ching sold $241,664 worth of stock or 15,000 shares.

Epizyme (NASDAQ:EPZM) Receives a Downgrade

RBC Capital decreased the rating for shares of Epizyme (NASDAQ:EPZM) to a”Sector Perform” from a “Outperform”. The rating change was published in a research report earlier today.

Investors sentiment increased to 1.93 in Q2 2017. Its up 0.87, from 1.06 in 2017Q1. It is positive, as 13 investors sold Epizyme Inc shares while 17 reduced holdings. 25 funds opened positions while 33 raised stakes. 47.46 million shares or 3.38% more from 45.91 million shares in 2017Q1 were reported.

The Illinois-based Gp One Trading Lp has invested 0% in Epizyme Inc (NASDAQ:EPZM). Woodstock Corp invested 0.11% in Epizyme Inc (NASDAQ:EPZM). Bb&T Limited Liability Co holds 0% or 12,000 shares. California-based First Republic Invest Mngmt has invested 0% in Epizyme Inc (NASDAQ:EPZM). Millennium Mgmt Limited Liability Company stated it has 0.01% of its portfolio in Epizyme Inc (NASDAQ:EPZM). Fmr Limited Co has 0.01% invested in Epizyme Inc (NASDAQ:EPZM). Financial Architects has invested 0.01% in Epizyme Inc (NASDAQ:EPZM). Deerfield Mngmt invested 0.53% of its portfolio in Epizyme Inc (NASDAQ:EPZM). Capital Fund Management holds 22,900 shares. Ny State Common Retirement Fund holds 41,400 shares or 0% of its portfolio. Renaissance Techs Limited Liability Co reported 200,788 shares stake. 1,955 were accumulated by Royal Financial Bank Of Canada. Baker Bros Advsr Lp stated it has 232,481 shares. Rock Springs Mgmt Lp holds 0.9% of its portfolio in Epizyme Inc (NASDAQ:EPZM) for 1.18M shares. Price T Rowe Assoc Inc Md accumulated 14,712 shares.

Since May 25, 2017, it had 0 insider purchases, and 2 sales for $275,289 activity. Ho Peter Tai-Ching sold $241,664 worth of stock or 15,000 shares.

Epizyme Inc (NASDAQ:EPZM) Ratings Coverage

Among 11 analysts covering Epizyme (NASDAQ:EPZM), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. Epizyme has $42 highest and $17 lowest target. $23.80’s average target is 82.38% above currents $13.05 stock price. Epizyme had 28 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating by Leerink Swann given on Thursday, June 15. SunTrust maintained Epizyme Inc (NASDAQ:EPZM) rating on Friday, October 27. SunTrust has “Buy” rating and $21.0 target. The company was maintained on Tuesday, May 10 by Mizuho. The firm has “Buy” rating given on Thursday, August 6 by Mizuho. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, June 7. H.C. Wainwright upgraded it to “Buy” rating and $25 target in Monday, March 14 report. On Wednesday, June 7 the stock rating was maintained by Cowen & Co with “Buy”. Oppenheimer maintained the shares of EPZM in report on Monday, July 24 with “Buy” rating. As per Friday, August 4, the company rating was maintained by RBC Capital Markets. On Thursday, September 14 the stock rating was maintained by RBC Capital Markets with “Buy”.

About 25,009 shares traded. Epizyme Inc (NASDAQ:EPZM) has risen 91.85% since November 14, 2016 and is uptrending. It has outperformed by 75.15% the S&P500.

Investors wait Epizyme Inc (NASDAQ:EPZM) to report on March, 8. its quarterly earnings Wall Street analysts expect $-0.57 earnings per share, up $0.03 or 5.00 % from last year’s $-0.6 same quarter earnings. Epizyme Inc’s Wall Street analysts see -9.52 % EPS growth, taking into account the $-0.63 EPS reproted in the previous quarter,

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $904.14 million. The Firm discovers, develops and plans to commercialize epigenetic therapies for cancer patients. It currently has negative earnings. The Firm is engaged in the discovery and development of novel epigenetic therapies for cancer patients.

More recent Epizyme Inc (NASDAQ:EPZM) news were published by: Globenewswire.com which released: “Epizyme to Present at the Jefferies 2017 London Healthcare Conference” on November 01, 2017. Also Globenewswire.com published the news titled: “Epizyme Announces Date of Third Quarter 2017 Financial Results” on October 25, 2017. Globenewswire.com‘s news article titled: “Epizyme Reports Third Quarter 2017 Operating Results and Company Updates” with publication date: November 01, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.